OSE Immunotherapeutics v2.2 Study OSE2101C301 (ATALANTE 1) Statistical Analysis Plan 2021 -07-23 IND#: BB-IND 10802 STATISTICAL ANALYSIS PLAN CONFIDENTIAL STATISTICAL ANALYSIS PLAN Protocol Title: A randomized parallel group phase III trial of OSE2101 as 2nd or 3rd line compared with standard treatment (docetaxel or pemetrexed) in HLA -A2 positive patients with advanced Non - Small -Cell Lung Cancer with progressive disease after last treatment with immune checkpoint inhibitors (ICI) (OSE2101C301) Protocol Number: OSE2101C301 (ATALANTE 1) Phase: Phase III Sponsor: OSE Immunotherapeutics 22 boulevard Benoni Goullin 44200 Nantes France Author: Summit Analytical, LLC 8354 Northfield Blvd. Bldg. G Suite 3700 Denver, CO 80238 SAP Date: 2021-07-23 Status: Draft v2.2_augmented after F DA Type C meeting (1st July 2021) SIGNATURES OSE Immunotherapeutics v2.2 Study OSE2101C301 (ATALANTE 1) Statistical Analysis Plan 2021 -07-23 IND#: BB-IND 10802 CONFIDENTIAL P a g e | 2/51 The undersigned have approved this Statistical Analysis Plan for use in this study. Napoléon Oleka Lead Biostatis tician Summit Analytical LLC Date Bérangère Vasseur, MD Chief Medical Officer Immuno -Oncology OSE Immunotherapeutics Date François Montestruc Statistician eXYSTAT Date OSE Immunotherapeutics v2.2 Study OSE2101C301 (ATALANTE 1) Statistical Analysis Plan 2021 -07-23 IND#: BB-IND 10802 CONFIDENTIAL P a g e | 3/51 1. TABLE OF CONTENTS 1.